Still Early Days for α-synuclein Fluid Marker
Well over a decade of research into fluid biomarker candidates has reached a point where a so-called “pathological signature” of amyloid-β and tau proteins is beginning to emerge...
ALL NEWS
471 RESULTS
Sort By:
- Most Recent
- Most Commented
Ordnung, Please—Can Biomarkers Tame a Bewildering Overlap?
Tangible progress in dealing with spectrum diseases will remain limited until the field comes up with more and better biomarkers of their component proteins...
ADNI: Mission Creep From Alzheimer Disease to Healthy Senior?
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) was originally conceived as an exploratory project to identify the best measures for tracking disease progression...
ADNI: One-year Data Narrow Field of MRI, FDG-PET Approaches
Alzheimer imaging aficionados gathered for a peek at the latest data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)...
HAI Seattle: Biomarkers Closing in on AD Pathological Sequence?
The earliest pathological underpinnings of Alzheimer disease often precede symptoms by untold numbers of years, presenting researchers with a two-edged sword...
Risky Business—New Index Predicts Dementia in Older Adults
Unfortunately, there is no quick test for predicting Alzheimer disease (AD)—at least not yet...
News Brief: Scientists Net Prizes for Progress Toward ALS Biomarker
The nonprofit Prize4Life is awarding two scientific teams with $50,000 each at the American Academy of Neurology annual meeting in Seattle, Washington, this week...
Studies Reveal New Hope, Old Problems With AD Biomarkers
Brain imaging and cognitive tests may be the gold standards for tracking AD progression, but clinical trials using these procedures are expensive, risky, and time-consuming...
ADNI: GWA Nearly Complete, Biomarker Analysis Update
The Alzheimer’s Disease Neuroimaging Initiative announced this week that its genomewide analysis is 95 percent complete...
Keystone: Pulse-Chasing AD Biomarkers, Snaring γ-Secretase Targets
Two things you can find on any Alzheimerologist’s wish list are better drug targets and better diagnostics...
Research Brief: New Methods for Aβ Detection, Production
So many different Aβs to measure, so little time—and funds...
DIAN Part 2: The Science, Inner Workings of the Network
Scientifically, the Dominantly Inherited Alzheimer Network (DIAN) will test three hypotheses...
Worldwide ADNIs: Other Nations Follow Suit
Around the time the North American ADNI started, similar efforts sprang up in countries across the globe...
Bumps Along the Way—ADNI’s Snafus
By common consensus of some 20 investigators contacted for this story from within and without ADNI, this behemoth study is working well overall...
More ADNI Results 2: It’s All About Power
One goal of ADNI is to make clinical trials sharper...